NCT01472016 - Study of ABT-700 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2011

Primary Completion Date

April 27, 2017

Study Completion Date

April 27, 2017

Conditions

Advanced Solid Tumors

Interventions

DRUG

ABT-700

ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

DRUG

docetaxel

Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.

DRUG

FOLFIRI

5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.

DRUG

cetuximab

Cetuximab will be administered by intravenous infusion weekly.

DRUG

erlotinib

Erlotinib will be taken orally daily.

DRUG

ABT-700

ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY